Meda acquires GSK's Relifex

Meda (SSE:MEDAa) acquired exclusive rights from GlaxoSmithkline (GSK; LSE:GSK) to Relifex nambumetone non-steroidal anti-inflammatory drug (NSAID) in European markets, including the U.K., the Netherla...